We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of CoQ10 Administration on Hemodialysis Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00307996
First Posted: March 28, 2006
Last Update Posted: March 28, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University of Shizuoka
  Purpose
The purpose of this study is to examine whether CoQ10 administration is effective as an antioxidant in hemodialysis patients.

Condition Intervention Phase
Chronic Renal Failure Hemodialysis Drug: Coenzyme Q10 (drug) Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Effect of CoQ10 Administration on the Oxidative and Antioxidative Markers in Hemodialysis Patients

Resource links provided by NLM:


Further study details as provided by University of Shizuoka:

Primary Outcome Measures:
  • Oxidative protein concentration at 6 month
  • Antioxidant capacity at 6 month

Estimated Enrollment: 40
Study Start Date: March 2004
Estimated Study Completion Date: December 2004
Detailed Description:
Oxidative stress has been recognized as a potential risk factor for such complications as atherosclerosis in hemodialysis patients. This study investigates whether CoQ10 administration is effective for protecting oxidative stress in hemodialysis patients. The subjects were recruited from day-time hemodialysis patients in Iwata City Hospital. 100 mg CoQ10 was administered every HD for 6 months. Several oxidative and antioxidative markers were measured in plasma at pre, 1, 3, 6 months and after washout.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hemodialysis for at least 6 months

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00307996


Locations
Japan
Iwata City Hospital
Iwata, Shizuoka, Japan, 438-8550
Sponsors and Collaborators
University of Shizuoka
Investigators
Study Chair: Hiromichi Kumagai, MD University of Shizuoka
  More Information

ClinicalTrials.gov Identifier: NCT00307996     History of Changes
Other Study ID Numbers: CT2006001
First Submitted: March 27, 2006
First Posted: March 28, 2006
Last Update Posted: March 28, 2006
Last Verified: March 2006

Keywords provided by University of Shizuoka:
CoQ10
hemodialysis
oxidative marker
antioxidant

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Failure, Chronic
Kidney Diseases
Urologic Diseases
Renal Insufficiency, Chronic
Coenzyme Q10
Ubiquinone
Micronutrients
Growth Substances
Physiological Effects of Drugs
Vitamins